1-8 of 8
Michael R Lassen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Venous Thromboembolism (VTE) Prevention with Semuloparin in Cancer Patients Initiating Chemotherapy: Benefit-Risk Assessment by VTE Risk in SAVE-ONCO

Daniel George, Giancarlo Agnelli, William Fisher, Ajay Kakkar, Michael R Lassen, Patrick Mismetti, Patrick Mouret, Francesca Lawson, Alexander G.G. Turpie
Journal: Blood
Blood (2011) 118 (21): 206.
https://doi.org/10.1182/blood.V118.21.206.206
Published: 2011
Journal Articles

The Ultra-Low-Molecular-Weight Heparin Semuloparin for Prevention of Venous Thromboembolism In Patients Undergoing Major Abdominal Surgery

Ajay K. Kakkar, MBBS, PhD, Giancarlo Agnelli, William D. Fisher, MD, Daniel George, Patrick Mouret, Michael R. Lassen, MD, Patrick Mismetti, Judith Murphy, Alexander G.G. Turpie
Journal: Blood
Blood (2010) 116 (21): 188.
https://doi.org/10.1182/blood.V116.21.188.188
Published: 2010
Journal Articles

Once Daily YM150, an Oral Direct Factor Xa Inhibitor, for Prevention of Venous Thromboembolism in Patients Undergoing Elective Primary Hip Replacement.

Bengt I. Eriksson, MD, PhD, Alexander G.G. Turpie, MD, PhD, Michael R. Lassen, MD, PhD, Martin H. Prins, MD, PhD, Giancarlo Agnelli, MD, PhD, Peter Kälebo, MD, PhD, Graham Wetherill, MSc, Lambertus Meems, MSc.
Journal: Blood
Blood (2007) 110 (11): 309.
https://doi.org/10.1182/blood.V110.11.309.309
Published: 2007
Journal Articles

AVE5026, a New Anticoagulant for the Prevention of Venous Thromboembolism in Total Knee Replacement Surgery - TREK: A Dose Ranging Study.

Michael R. Lassen, MD, Ola E. Dahl, MD, Patrick Mismetti, MD, Dominique Destrée, MD
Journal: Blood
Blood (2007) 110 (11): 311.
https://doi.org/10.1182/blood.V110.11.311.311
Published: 2007
Journal Articles

Rivaroxaban - An Oral, Direct Factor Xa Inhibitor - for Thromboprophylaxis after Total Knee Arthoplasty: The RECORD3 Trial.

Michael R. Lassen, MD, Alexander G.G. Turpie, MD, Nadia Rosencher, MD, Lars C. Borris, MD, Walter Ageno, MD, Jay R. Lieberman, MD, Tiemo J. Bandel, MD, Frank Misselwitz, MD, PhD
Journal: Blood
Blood (2007) 110 (11): 308.
https://doi.org/10.1182/blood.V110.11.308.308
Published: 2007
Journal Articles

A Phase II Randomized, Double-Blind, Eight-Arm, Parallel-Group, Dose-Response Study of Apixaban, a New Oral Factor Xa Inhibitor for the Prevention of Deep Vein Thrombosis in Knee Replacement Surgery - On Behalf of the Apixaban Investigators.

Michael R. Lassen, MD, Bruce L. Davidson, MD, Alexander Gallus, MD, Graham Pineo, MD, Jack Ansell, MD, David Deitchman, PhD
Journal: Blood
Blood (2006) 108 (11): 574.
https://doi.org/10.1182/blood.V108.11.574.574
Published: 2006
Journal Articles

YM150, an Oral Direct Factor Xa Inhibitor, as Prophylaxis for Venous Thromboembolism in Patients with Elective Primary Hip Replacement Surgery. A Dose Escalation Study.

Bengt I. Eriksson, MD, Alexander G.G. Turpie, MD, Michael R. Lassen, MD, Martin H. Prins, MD, Giancarlo Agnelli, MD, Marleen L. Gaillard, PhD, Bert Meems, MSc
Journal: Blood
Blood (2005) 106 (11): 1865.
https://doi.org/10.1182/blood.V106.11.1865.1865
Published: 2005
Journal Articles

Benefit of Fondaparinux in Medical Patients: A Subgroup Analysis.

Alexander T. Cohen, Alexander S. Gallus, Bruce L. Davidson, Michael R. Lassen, Martin H. Prins, Witold Tomkowski, Alexander G.G. Turpie, Jan F.M. Egberts, Anthonie W.A. Lensing
Journal: Blood
Blood (2004) 104 (11): 4079.
https://doi.org/10.1182/blood.V104.11.4079.4079
Published: 2004